Black Cohosh (Actaea racemosa): Evidence, Dosage & Uses

Q: What is the typical black cohosh dosage?

Studies and regulatory guidance cite 40 to 80 mg of dry extract per day as the standardized dosing range for menopausal symptom relief.

French Pharmacopoeia List A · Ranunculaceae

Biological Overview

Actaea racemosa is a vigorous herbaceous plant native to North America (Canada and the United States), capable of reaching 2 meters in height. It has large compound leaves with incised, toothed leaflets, and small white flowers arranged in tall, branching racemes.

HabitVigorous Perennial, to 2m

Native RangeNorth America

Usual Dosage40–80 mg/day dry extract

Regulatory StatusFr. Pharmacopoeia List A

Botanical Classification

Taxonomy & Identification

Latin Name: Actaea racemosa L.
Synonym: Cimicifuga racemosa (L.) Nutt.
Family: Ranunculaceae
Common Names: Black Cohosh, Black Snakeroot, Bugbane
Parts Used: Underground parts — rhizome and adjacent roots
Origin: North America (Canada, United States)

Ethnobotany & Traditional Use

History & Tradition

Black cohosh was used by Native American tribes for an unusually broad range of complaints: rheumatism, sore throats, kidney disease, malaria, bronchitis, chorea, dropsy, fever, hysteria, amenorrhea, and menstrual disorders — and to help speed labor via its stimulating effect on uterine contractions.

The root was formally listed in the British Pharmacopoeia until the early 20th century, reflecting its adoption into conventional Western herbal practice well beyond its indigenous origins.

Notably, black cohosh's effects have been observed to be considerably more pronounced in women than in men — a distinction consistent with its centuries-long focus on female reproductive and menstrual health.

⚠ Sex-Specific Efficacy Observed

Black cohosh's effects have been observed to be notably more pronounced in women than men — a distinction worth knowing since much of its traditional and clinical use centers on female reproductive and menopausal physiology.

Timeline

Native American Use

Pre-Colonial

Used for rheumatism, sore throats, kidney disease, malaria, bronchitis, chorea, dropsy, fever, hysteria, and menstrual disorders, and to help speed labor.

British Pharmacopoeia Listing

19th–Early 20th Century

Formally listed in the British Pharmacopoeia until the early 20th century.

Menopause-Focused Clinical Research

Late 20th Century

Modern clinical trials began focusing specifically on menopausal symptom relief. ¹⁸¹⁹²⁰

Mechanism & Regulatory Recognition

2000s–Present

A central (rather than purely peripheral hormonal) mechanism was proposed, and black cohosh gained recognition from the EMA, WHO, German Commission E, and ESCOP. ¹⁰

The Key Compounds

Actein & Formononetin — Deep Dive

The triterpene glycoside and isoflavone pairing behind black cohosh's estrogen-receptor-modulating and anti-proliferative research.

🧬

Cycloartane-Type Triterpenes

Actein and cimicifugoside are tetracyclic triterpenes derived from cycloartanol, alongside cimiracemosides A–H and cimigenol. ²

🔗

Formononetin & Estrogen Receptor Binding

The isoflavone formononetin binds estrogen receptors and shows a described dopaminergic effect. ³

🎯

SERM-Like Activity

Evidence points to selective estrogen receptor modulator-like activity, in some respects comparable to estradiol-17beta — though a literature review suggests black cohosh's action is more central than a direct peripheral hormonal effect. ⁸¹⁰

🧫

Anti-Proliferative Triterpenoid Activity

Actein and related triterpene glycosides inhibit growth of human breast cancer cell lines and induce apoptosis in HER2-overexpressing lines. ¹⁴¹⁵¹⁶

⚠ Not a Breast Cancer Treatment

In vitro signal does not translate to a treatment claim.

In vitro, black cohosh's triterpenes show growth-inhibiting activity against breast cancer cells and appear to blunt estradiol's effects, with a possible synergistic effect alongside tamoxifen. This does not mean black cohosh can serve as a breast cancer treatment, nor that it's free of long-term concerns — women with a personal history of hormone-dependent cancer are generally advised to avoid it.

Pharmaceutical Preparations

Parts Used & Available Forms

The underground parts — rhizome and adjacent roots — are used medicinally, prepared across two documented forms.

Mother Tincture

Tincture of the underground parts, used at practitioner-directed dilution.

Mother Tincture

Dry Extract

Concentrated dry root extract, the standardized form studied in most clinical trials.

Dry Extract

Clinical Dosimetry

Dosages

Standardized dry-extract dosing reflects the range cited across clinical trials and regulatory recognition; duration should be guided by a qualified practitioner.

Form	Dose	Frequency	Notes
Dry Extract	40–80 mg	Daily	Standardized dosing range cited for menopausal symptom relief. ¹

Phytochemistry

Composition

Root and rhizome composition only — no gemmotherapy (bud) or essential-oil fraction is documented for this species.

Root & Rhizome — Primary Constituents

Flavonoids (Isoflavones)Includes formononetin, an isoflavone with estrogenic activity

Present

Tetracyclic TriterpenesCycloartanol derivatives — actein, cimifugoside, cimiracemosides A–H, cimigenol ²

Present

TanninsStructural polyphenolic constituents

Present

Phenolic AcidsMinor bioactive constituents

Present

AlkaloidsIncludes cytisine and methyl-cytisine

Present

Sugars & Fatty AcidsGeneral plant constituents

Present

Plant Properties — Pharmacodynamics

Eight pharmacodynamic properties are documented for black cohosh, spanning hormonal, vascular, and anti-proliferative pathways.

8 Properties SERM-Like Anti-inflammatory Clinical + Preclinical

🔥

Anti-inflammatory

Documented anti-inflammatory activity alongside diuretic action.

💧

Diuretic

Traditionally and pharmacologically recognized diuretic effect.

🎯

Estrogen Receptor Modulating

Formononetin binds estrogen receptors; extracts also show anti-estrogenic and receptor-modulating activity depending on context. ³⁸⁹

🦴

Osteoblastic

Shows osteoblastic (bone-supportive) activity and a mild estrogenic effect on vaginal mucosa. ⁸¹¹

🩸

Vasodilatory / Hypotensive

Vasodilatory and hypotensive activity, including vascular effects on the inner ear.

🌀

Antispasmodic & Sedative

Traditionally used for its antispasmodic and sedative properties.

🧫

Anti-proliferative (Breast)

Triterpenoids including actein inhibit growth of human breast cancer cell lines. ¹⁴¹⁵¹⁶

🔬

Anti-proliferative (Prostate)

Extract BNO 1055 inhibits proliferation of the LNCaP human prostate cancer cell line. ²⁸²⁹

Clinical Applications

Clinical Indications

Black cohosh's primary use is menopausal symptom relief, with efficacy that remains debated across the clinical evidence base.

🌡️

Menopausal Symptom Relief

Primary Indication — Debated Efficacy

Multiple RCTs Support Benefit: including a 12-week, randomized, double-blind, placebo-controlled trial in 180 patients with climacteric complaints. ¹⁸²³
Some Reviews Disagree: other systematic reviews conclude that clinical efficacy hasn't been convincingly demonstrated by rigorous trials. ²⁴²⁵

🩸

Gynecological & Hormonal Regulation

Traditional Indication

Steroid Insufficiency in Women: hormonal regulation in dysmenorrhea and climacteric syndrome. ²⁶

😊

Mood in Menopause

Research-Backed Indication

Mood Improvement: improvement of mood disturbances in menopausal women, possibly via a serotonergic effect. ²⁷
With St. John's Wort: a combination of St. John's Wort and black cohosh has been reported to work as well as hormone therapy for menopausal complaints without the same side effects, with roughly 78% good results reported for hot flashes in that combination.

🔬

Investigational & Other Uses

Preliminary / Traditional

Prostate Cancer Cell Lines (Preliminary): inhibits proliferation of certain prostate cancer cell lines in vitro. ²⁸²⁹
ENT & Cardiovascular (Traditional): tinnitus and hypertension are noted uses, though the source itself flags these as tentative.

Pharmacodynamics

Mode of Action

Black cohosh's effect on menopausal symptoms draws on receptor-modulating activity and central nervous system pathways rather than direct hormone replacement.

📉

LH Suppression & Estrogen Receptor Modulation

Reduces LH levels in ovariectomized rats, with estrogen receptor modulating activity and osteoblastic action. ⁸⁹

🧠

Opioid & Serotonin Receptor Activity for Hot Flashes

Acts on mu opioid (hMOR) receptors and shows a serotonergic effect — proposed mechanisms for hot-flash relief. ¹²¹³

🧬

Central Rather Than Peripheral Hormonal Action

A literature review suggests black cohosh's activity is more central (neurological) than a direct peripheral hormonal effect. ¹⁰

👂

Vascular Effects on the Inner Ear

Hypotensive and vasodilatory action includes vascular effects on the inner ear, relevant to reported traditional use for tinnitus.

Comparative Analysis

Black Cohosh vs Hormone Replacement Therapy

A non-hormonal botanical option set against the pharmaceutical standard for menopausal symptom management.

Criterion	Black Cohosh	HRT
Mechanism	SERM-like / central neurological action (opioid & serotonin receptors), not direct estrogen replacement	Direct estrogen (often combined with progestin) replacement
Evidence Base	Multiple RCTs, though efficacy is debated across systematic reviews	Extensive RCT evidence with well-established efficacy for vasomotor symptoms
Hormone-Dependent Cancer	⚠ Generally avoided as a precaution despite some in vitro anti-proliferative signal	⚠ Contraindicated in most hormone-dependent cancers; can increase certain cancer risks with prolonged use
Side Effect Profile	Mostly mild GI upset; rare hepatotoxicity reports	Broader risk range, including blood clots, stroke, and breast cancer risk with prolonged combined use
Duration of Use	Typically used for defined courses to manage symptoms	Can be used short- or longer-term under medical supervision, with periodic risk reassessment
Regulatory Status	Recognized by EMA, WHO, German Commission E, ESCOP; Fr. Pharmacopoeia List A	Prescription medication regulated as a pharmaceutical

Bottom Line

Black cohosh offers a non-hormone-replacement option for menopausal symptom relief with a comparatively mild side-effect profile, though its clinical efficacy is debated across systematic reviews. HRT has stronger, more consistent evidence for symptom control but carries a different risk profile. The choice between them is a personal, medically-guided decision rather than a clear-cut answer.

Risk Profile

Safety & Interactions

Black cohosh's safety profile centers on rare hepatotoxicity reports, hormone-dependent cancer caution, and pregnancy avoidance.

⚠ Genuine Risks Specific to This Plant

Read Before Using Black Cohosh

Hepatotoxicity risk: case reports describe fulminant liver failure and autoimmune hepatitis associated with black cohosh use, though other studies found no notable toxicity risk. ³⁰³¹³²
Hormone-dependent cancer caution: avoid in women with a history of breast cancer or other hormone-dependent disease given additive estrogenic effects. ³⁴
Pregnancy & breastfeeding: not recommended due to insufficient data; traditionally used to stimulate uterine contractions and speed labor, underscoring the pregnancy caution.
Drug transporter interaction: interacts with the OATP2B1 transporter, potentially reducing efficacy of amiodarone, fexofenadine, glibenclamide, and statins.

✓ How to Use Black Cohosh More Safely

A Practical Safety Checklist

Watch your liver. Report unusual fatigue, jaundice, or abdominal pain promptly; rare but serious hepatotoxicity has been reported.
Avoid with a hormone-dependent condition. Skip black cohosh with a personal history of breast cancer or other hormone-sensitive disease.
Never use during pregnancy. Its traditional use to stimulate labor reflects a real uterine-stimulating action best avoided earlier in pregnancy.
Mind specific drug interactions. Particularly amiodarone, fexofenadine, glibenclamide, and statins, given the OATP2B1 transporter interaction.
Use standardized extract. Stick to the studied 40–80 mg/day dry-extract range rather than improvised dosing.
Talk to a provider first if breastfeeding, on hepatotoxic medications, or managing a chronic condition.

⚠️

Adverse Effects

GI Upset: gastric disturbances are the most commonly reported adverse effect.
Hepatotoxicity (Rare): case reports describe fulminant liver failure and autoimmune hepatitis, though other studies found no notable toxicity risk. ³⁰³¹³²
CYP3A4 Inhibition: triterpenes inhibit CYP3A4, though overall cytochrome P450 interaction is limited; no interaction with P-glycoprotein. ³³

🚫

Contraindications & Interactions

Hormone-Dependent Disease: avoid with a history of breast cancer or other hormone-dependent condition given additive estrogenic effects. ³⁴
Pregnancy & Breastfeeding: not recommended given insufficient safety data.
Transporter Interaction: interacts with OATP2B1, potentially reducing efficacy of amiodarone, fexofenadine, glibenclamide, and statins.

Clinical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice. Consult a qualified healthcare provider before starting black cohosh, particularly if pregnant, breastfeeding, have a history of hormone-dependent cancer, or take other medications.

Common Questions

Frequently Asked Questions

What is black cohosh used for?

Black cohosh is used primarily for menopausal symptoms such as hot flashes and mood disturbances, and traditionally for menstrual disorders, rheumatism, and other complaints among Native American tribes.

How does black cohosh work for menopause symptoms?

Its triterpene glycosides and the isoflavone formononetin show selective estrogen receptor modulator-like activity, and research suggests black cohosh acts on opioid and serotonin receptors to relieve hot flashes, with evidence pointing toward a more central than peripheral hormonal mechanism.

Is black cohosh safe for the liver?

Rare case reports describe fulminant liver failure and autoimmune hepatitis associated with black cohosh use, though other studies found no notable toxicity risk. Anyone with liver concerns should discuss use with a healthcare provider.

What is the typical black cohosh dosage?

Studies and regulatory guidance cite 40–80 mg of dry extract per day as the standardized dosing range for menopausal symptom relief.

Can I take black cohosh if I've had breast cancer?

It's generally not recommended. Black cohosh is advised against in women with a history of breast cancer or other hormone-dependent disease, given its additive estrogenic effects, even though some in vitro research shows a growth-inhibiting signal against certain cancer cell lines.

Is black cohosh safe during pregnancy?

No. Its use is not recommended during pregnancy or breastfeeding due to insufficient safety data, and it was traditionally used to stimulate uterine contractions and speed labor.

Does black cohosh really work for hot flashes?

Evidence is mixed. Several randomized controlled trials report improvement in menopausal symptoms, but some systematic reviews conclude that clinical efficacy hasn't been convincingly demonstrated by rigorous trials.

Black cohosh vs HRT — which should I consider?

Black cohosh offers a non-hormone-replacement option with a comparatively mild side-effect profile, though its efficacy is debated. HRT has stronger, more consistent evidence for symptom control but carries a different risk profile. This is a personal decision best made with a healthcare provider.

Sources

Bibliography

↑1. Mahady GB. Black cohosh (Actaea/Cimicifuga racemosa): review of the clinical data for safety and efficacy in menopausal symptoms. Treat Endocrinol. 2005;4(3):177–184.
PubMed: PMID 15898823 →

↑2. Shao Y, Harris A, Wang M, et al. Triterpene glycosides from Cimicifuga racemosa. J Nat Prod. 2000;63(7):905–910.
PubMed: PMID 10924163 →

↑3. Jarry H, Metten M, Spengler B, Christoffel V, Wuttke W. In vitro effects of the Cimicifuga racemosa extract BNO 1055. Maturitas. 2003;44 Suppl 1:S31–S38.
PubMed: PMID 12609557 →

↑4. Zierau O, Bodinet C, Kolba S, Wulf M, Vollmer G. Antiestrogenic activities of Cimicifuga racemosa extracts. J Steroid Biochem Mol Biol. 2002;80(1):125–130.
PubMed: PMID 11867271 →

↑5. Bodinet C, Freudenstein J. Influence of Cimicifuga racemosa on the proliferation of estrogen receptor-positive human breast cancer cells. Breast Cancer Res Treat. 2002;76(1):1–10.
PubMed: PMID 12408370 →

↑6. Hostanska K, Nisslein T, Freudenstein J, Reichling J, Saller R. Cimicifuga racemosa extract inhibits proliferation of estrogen receptor-positive and negative human breast carcinoma cell lines by induction of apoptosis. Breast Cancer Res Treat. 2004;84(2):151–160.
PubMed: PMID 14999145 →

↑7. Hernández Muñoz G, Pluchino S. Cimicifuga racemosa for the treatment of hot flushes in women surviving breast cancer. Maturitas. 2003;44 Suppl 1:S59–S65.
PubMed: PMID 12609560 →

↑8. Seidlova-Wuttke D, Hesse O, Jarry H, et al. Evidence for selective estrogen receptor modulator activity in a black cohosh (Cimicifuga racemosa) extract: comparison with estradiol-17beta. Eur J Endocrinol. 2003;149(4):351–362.
PubMed: PMID 14514351 →

↑9. Düker EM, Kopanski L, Jarry H, Wuttke W. Effects of extracts from Cimicifuga racemosa on gonadotropin release in menopausal women and ovariectomized rats. Planta Med. 1991;57(5):420–424.
PubMed: PMID 1798794 →

↑10. Borrelli F, Izzo AA, Ernst E. Pharmacological effects of Cimicifuga racemosa. Life Sci. 2003;73(10):1215–1229.
PubMed: PMID 12850238 →

↑11. Wuttke W, Gorkow C. Effects of black cohosh (Cimicifuga racemosa) on bone turnover, vaginal mucosa, and various blood parameters in postmenopausal women. Menopause. 2006;13(2):185–196.
PubMed: PMID 16645532 →

↑12. Rhyu MR, Lu J, Webster DE, Fabricant DS, Farnsworth NR, Wang ZJ. Black cohosh (Actaea racemosa, Cimicifuga racemosa) behaves as a mixed competitive ligand and partial agonist at the human mu opiate receptor. J Agric Food Chem. 2006;54(26):9852–9857.
PubMed: PMID 17177511 →

↑13. Burdette JE, Liu J, Chen SN, et al. Black cohosh acts as a mixed competitive ligand and partial agonist of the serotonin receptor. J Agric Food Chem. 2003;51(19):5661–5670.
PubMed: PMID 12952416 →

↑14. Einbond LS, Shimizu M, Nuntanakorn P, et al. Actein and a fraction of black cohosh potentiate antiproliferative effects of chemotherapy agents on human breast cancer cells. Planta Med. 2006;72(13):1200–1206.

↑15. Einbond LS, Shimizu M, Xiao D, et al. Growth inhibitory activity of extracts and purified components of black cohosh on human breast cancer cells. Breast Cancer Res Treat. 2004;83(3):221–231.

↑16. Einbond LS, Wen-Cai Y, He K, et al. Growth inhibitory activity of extracts and compounds from Cimicifuga species on human breast cancer cells. Phytomedicine. 2008;15(6-7):504–511.
PubMed: PMID 17980565 →

↑17. Jöhrer K, Stuppner H, Greil R, Çiçek SS. Structure-guided identification of black cohosh (Actaea racemosa) triterpenoids with in vitro activity against multiple myeloma. Molecules. 2020;25(4):766.
PubMed: PMID 32053921 →

↑18. Lieberman S. A review of the effectiveness of Cimicifuga racemosa (black cohosh) for the symptoms of menopause. J Womens Health. 1998;7(5):525–529.
PubMed: PMID 9650153 →

↑19. Nappi RE, Malavasi B, Brundu B, Facchinetti F. Efficacy of Cimicifuga racemosa on climacteric complaints: a randomized study versus low-dose transdermal estradiol. Gynecol Endocrinol. 2005;20(1):30–35.
PubMed: PMID 15969244 →

↑20. Frei-Kleiner S, Schaffner W, Rahlfs VW, Bodmer C, Birkhäuser M. Cimicifuga racemosa dried ethanolic extract in menopausal disorders: a double-blind placebo-controlled clinical trial. Maturitas. 2005;51(4):397–404.
PubMed: PMID 16039414 →

↑21. Mohammad-Alizadeh-Charandabi S, Shahnazi M, Nahaee J, Bayatipayan S. Efficacy of black cohosh (Cimicifuga racemosa L.) in treating early symptoms of menopause: a randomized clinical trial. Chin Med. 2013;8(1):20.
PubMed: PMID 24499633 →

↑22. Uebelhack R, Blohmer JU, Graubaum HJ, Busch R, Gruenwald J, Wernecke KD. Black cohosh and St. John's wort for climacteric complaints: a randomized trial. Obstet Gynecol. 2006;107(2 Pt 1):247–255.

↑23. Schellenberg R, Saller R, Hess L, et al. Dose-dependent effects of the Cimicifuga racemosa extract Ze 450 in the treatment of climacteric complaints: a randomized, placebo-controlled study. Evid Based Complement Alternat Med. 2012;2012:260301.
PubMed: PMID 23346194 →

↑24. Borrelli F, Ernst E. Cimicifuga racemosa: a systematic review of its clinical efficacy. Eur J Clin Pharmacol. 2002;58(4):235–241.

↑25. Borrelli F, Ernst E. Black cohosh (Cimicifuga racemosa) for menopausal symptoms: a systematic review of its efficacy. Pharmacol Res. 2008;58(1):8–14.
PubMed: PMID 18585461 →

↑26. Liske E. Therapeutic efficacy and safety of Cimicifuga racemosa for gynecologic disorders. Adv Ther. 1998;15(1).
PubMed: PMID 10178637 →

↑27. Geller SE, Studee L. Contemporary alternatives to plant estrogens for menopause. Maturitas. 2006;55 Suppl 1:S3–S13.
PubMed: PMID 16884867 →

↑28. Jarry H, Thelen P, Christoffel V, Spengler B, Wuttke W. Cimicifuga racemosa extract BNO 1055 inhibits proliferation of the human prostate cancer cell line LNCaP. Phytomedicine. 2005;12(3):178–182.
PubMed: PMID 15830838 →

↑29. Seidlová-Wuttke D, Thelen P, Wuttke W. Inhibitory effects of a black cohosh (Cimicifuga racemosa) extract on prostate cancer. Planta Med. 2006;72(6):521–526.
PubMed: PMID 16773536 →

↑30. Levitsky J, Alli TA, Wisecarver J, Sorrell MF. Fulminant liver failure associated with the use of black cohosh. Dig Dis Sci. 2005;50(3):538–539.
PubMed: PMID 15810638 →

↑31. Cohen SM, O'Connor AM, Hart J, et al. Autoimmune hepatitis associated with the use of black cohosh: a case study. Menopause. 2004;11:575–577.
PubMed: PMID 15356412 →

↑32. Low Dog T, Powell KL, Weisman SM. Critical evaluation of the safety of Cimicifuga racemosa in menopause symptom relief. Menopause. 2003;10(4):299–313.
PubMed: PMID 12851513 →

↑33. Tsukamoto S, Aburatani M, Ohta T. Isolation of CYP3A4 inhibitors from the black cohosh (Cimicifuga racemosa). Evid Based Complement Alternat Med. 2005.
Full Text →

↑34. Mayo Clinic. Black cohosh (Cimicifuga racemosa [L.] Nutt.). 2010.
Reference Page →

Additional Sources

Shams T, Setia MS, Hemmings R, McCusker J, Sewitch M, Ciampi A. Efficacy of black cohosh-containing preparations on menopausal symptoms: a meta-analysis. Altern Ther Health Med. 2010;16(1):36–44.
PubMed: PMID 20085176 →

Borrelli F, Ernst E. Alternative and complementary therapies for the menopause. Maturitas. 2010;66(4):333–343.
PubMed: PMID 20580501 →

Osmers R, Friede M, Liske E, Schnitker J, Freudenstein J, Henneicke-von Zepelin HH. Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms. Obstet Gynecol. 2005;105(5 Pt 1):1074–1083.
PubMed: PMID 15863547 →